tariquidar has been researched along with Experimental Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, Y; Liu, XX; Qi, JG; Ren, QW; Tian, JW; Wang, BH; Wang, HB; Wang, X; Yang, YT; Zhai, R | 1 |
| Bootle, D; Charlton, P; Dangerfield, W; Liddle, C; Mistry, P; Okiji, S; Plumb, JA; Stewart, AJ; Templeton, D | 1 |
2 other study(ies) available for tariquidar and Experimental Neoplasms
| Article | Year |
|---|---|
Synthesis and biological evaluation of novel H6 analogues as drug resistance reversal agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Oleanolic Acid; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Topics: Acridines; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Binding, Competitive; Cell Division; Cyclosporins; Daunorubicin; Dihydropyridines; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Isoquinolines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Quinolines; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Tritium; Xenograft Model Antitumor Assays | 2001 |